Form 4: Coherus CEO Boosts Stake with RSU and Option Grants

Coherus Oncology's President & CEO, Dennis M. Lanfear, acquired 375,000 restricted stock units and 750,000 stock options on January 23, 2026.

Summary

• Dennis M. Lanfear, President & CEO and Director of Coherus Oncology, Inc. (CHRS), acquired 375,000 restricted stock units (RSUs) and 750,000 stock options on January 23, 2026.
• The 375,000 RSUs entitle Mr. Lanfear to receive one share of Common Stock per RSU upon vesting, with 50% vesting on May 20, 2027, and the remaining 50% vesting on March 20, 2029, contingent on his continued service.
• The 750,000 stock options have an exercise price of $2.06 per share and will vest as to 1/4th of the total shares on January 23, 2027, and then in successive, equal monthly installments of 1/48th thereafter, subject to continued service.
• The stock options have an expiration date of January 23, 2036.
• Following these transactions, Mr. Lanfear directly beneficially owns 1,048,235 shares of Common Stock and 750,000 derivative securities (stock options).
• Additionally, 432,684 shares are indirectly held by the Lanfear Revocable Trust, and 86,965 shares are indirectly held by Lanfear Capital Advisors, LLC.

Sentiment

Score: 8

Explanation: The sentiment is positive as the CEO is increasing their stake in the company through equity grants, signaling confidence in the company's future prospects and aligning their interests with shareholders. This is generally viewed favorably by the market.

Positives

• The acquisition of a significant number of restricted stock units and stock options by the President & CEO indicates strong insider confidence in the company's future performance and strategic direction.
• Equity grants align management's interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedules for both RSUs and stock options encourage the CEO's continued service and commitment to the company over several years.

Future Outlook

The equity grants, with their multi-year vesting schedules extending to 2029 for RSUs and 2036 for options, indicate an expectation of the CEO's continued long-term service and commitment to Coherus Oncology's strategic objectives and growth.

Industry Context

This insider transaction reflects a standard practice in the biotechnology and pharmaceutical industry where executive compensation packages often include significant equity components to attract, retain, and incentivize leadership. Such grants are designed to align executive performance with shareholder returns over the long term, a common strategy in a sector characterized by lengthy development cycles and high R&D costs.

Comparison to Industry Standards

• The structure of equity compensation, including both RSUs and stock options with multi-year vesting, is consistent with executive compensation practices observed in comparable biopharmaceutical companies.
• The volume of shares granted to a CEO in a company of Coherus Oncology's market capitalization is within typical ranges for performance-based incentives, aiming to provide substantial upside potential tied to company success.

Related Party Transactions

• The shares indirectly held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which the Reporting Person is a trustee.
• The shares indirectly held by Lanfear Capital Advisors, LLC, of which the Reporting Person is President.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's financial interests with long-term shareholder value creation.
• Employees: May signal stability and confidence in leadership, potentially boosting morale.
• Management: Provides significant long-term incentives for the CEO to drive company performance.

Next Steps

• The Restricted Stock Units will vest 50% on May 20, 2027, and 50% on March 20, 2029, subject to continued service.
• The stock options will begin vesting on January 23, 2027, with 1/4th of the total shares, followed by monthly installments thereafter, subject to continued service.

Key Dates

Recommendation

While a Form 4 filing primarily reports insider transactions and does not provide a comprehensive financial overview, the significant equity grants to the CEO, Dennis M. Lanfear, suggest strong insider confidence in Coherus Oncology's future. This insider buying, particularly by a key executive, can be a positive signal for investors, indicating that management believes the stock is undervalued or has significant upside potential. However, without broader financial context, a 'hold' recommendation is prudent, acknowledging the positive insider sentiment while awaiting more comprehensive financial disclosures for a stronger stance.

Keywords

Coherus Oncology, CHRS, Dennis M. Lanfear, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, CEO Compensation